gliclazide and Peripheral Arterial Disease studies

gliclazide and Peripheral Arterial Disease

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Peripheral Arterial Disease: Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.

Research Excerpts

Excerpt	Relevance	Reference
"We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) clinical trial."	2.82	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. ( Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S, 2016)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Mohammedi, K	1
Woodward, M	1
Hirakawa, Y	1
Zoungas, S	1
Williams, B	1
Lisheng, L	1
Rodgers, A	1
Mancia, G	1
Neal, B	1
Harrap, S	1
Marre, M	1
Chalmers, J	1

Studies

Mohammedi, K

Woodward, M

Hirakawa, Y

Zoungas, S

Williams, B

Lisheng, L

Rodgers, A

Mancia, G

Neal, B

Harrap, S

Marre, M

Chalmers, J

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]	Phase 3	11,140 participants (Actual)	Interventional	2001-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]

Phase 3

11,140 participants (Actual)

Interventional

2001-06-30

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for gliclazide and Peripheral Arterial Disease

Article	Year
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. Diabetes care, 2016, Volume: 39, Issue:10 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F	2016

Article

Year

Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.

Diabetes care, 2016, Volume: 39, Issue:10

Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F

2016